Why did RPTX's Q3 and Q4 2024 earnings drop to zero?

The earnings of Repare Therapeutics Inc. (RPTX) dropped to zero in Q3 and Q4 2024 due to a combination of factors:

1. **Revenue from Collaboration Agreements**: Repare Therapeutics did not generate any revenue from collaboration agreements during Q3 2024, which is a significant decrease from the $2.2 million in the same quarter of the previous year. This decrease is attributed to the termination of the Roche Agreement and the expiration of the BMS Agreement.
2. **Research and Development Expenses**: The company's research and development (R&D) expenses decreased to $28.4 million in Q3 2024, down from $32.7 million in the same quarter of the previous year. This decrease is primarily due to reduced external costs for the camonsertib and lunresertib programs.
3. **General and Administrative Expenses**: General and administrative expenses also decreased to $6.4 million in Q3 2024, down from $7.9 million in the same quarter of the previous year, mainly due to lower personnel-related costs and share-based compensation.
4. **Restructuring Expenses**: Repare incurred $1.5 million in restructuring expenses during Q3 2024, related to a strategic reprioritization that resulted in a workforce reduction of approximately 25%.

In summary, the drop in RPTX's Q3 and Q4 2024 earnings can be attributed to the lack of revenue from collaboration agreements, reduced research and development and general and administrative expenses, and restructuring expenses.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|RPTX|RPTX.O|Repare|2024 Q1|136.144578313253|0.3|185|
|RPTX|RPTX.O|Repare|2024 Q2|-192.8571428571428|-0.82|185|
|RPTX|RPTX.O|Repare|2024 Q3|-80|-0.81|185|